- Home
- TBPH vs EIM Comparison
TBPH vs EIM Comparison
Compare TBPH & EIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- EIM
- Stock Information
- Founded
- TBPH 2013
- EIM 2002
- Country
- TBPH United States
- EIM United States
- Employees
- TBPH N/A
- EIM N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- EIM Finance/Investors Services
- Sector
- TBPH Health Care
- EIM Finance
- Exchange
- TBPH Nasdaq
- EIM Nasdaq
- Market Cap
- TBPH 699.0M
- EIM 561.3M
- IPO Year
- TBPH N/A
- EIM N/A
- Fundamental
- Price
- TBPH $14.26
- EIM $9.83
- Analyst Decision
- TBPH Strong Buy
- EIM
- Analyst Count
- TBPH 4
- EIM 0
- Target Price
- TBPH $23.00
- EIM N/A
- AVG Volume (30 Days)
- TBPH 301.7K
- EIM 215.2K
- Earning Date
- TBPH 11-11-2025
- EIM 01-01-0001
- Dividend Yield
- TBPH N/A
- EIM 4.32%
- EPS Growth
- TBPH N/A
- EIM N/A
- EPS
- TBPH 0.26
- EIM N/A
- Revenue
- TBPH $77,205,000.00
- EIM N/A
- Revenue This Year
- TBPH $79.82
- EIM N/A
- Revenue Next Year
- TBPH N/A
- EIM N/A
- P/E Ratio
- TBPH $54.87
- EIM N/A
- Revenue Growth
- TBPH 24.49
- EIM N/A
- 52 Week Low
- TBPH $7.90
- EIM $8.61
- 52 Week High
- TBPH $15.15
- EIM $10.51
- Technical
- Relative Strength Index (RSI)
- TBPH 54.96
- EIM 40.46
- Support Level
- TBPH $13.50
- EIM $9.88
- Resistance Level
- TBPH $14.59
- EIM $9.99
- Average True Range (ATR)
- TBPH 0.50
- EIM 0.08
- MACD
- TBPH -0.09
- EIM -0.02
- Stochastic Oscillator
- TBPH 46.31
- EIM 11.76
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.